Skip to main content
. 2023 Apr 29;15(9):2560. doi: 10.3390/cancers15092560

Figure 2.

Figure 2

Change in T2-weighted FLAIR-hyperintensity and T1-weighted gadolinium enhancing volumes between baseline MRI and the most recent MRI at the end of BEV treatment (first row). Evolution in time of T2-weighted FLAIR-hyperintensity and T1-weighted gadolinium enhancing volumes during treatment (second row). * Indicates a re-challenge with a low-dose bevacizumab regimen after an elective discontinuation of bevacizumab treatment.